Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP raised its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 51.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,500 shares of the company's stock after purchasing an additional 24,300 shares during the period. Two Sigma Advisers LP owned about 0.16% of Apogee Therapeutics worth $3,239,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in APGE. Barclays PLC grew its stake in shares of Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company's stock worth $21,443,000 after purchasing an additional 287,243 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Apogee Therapeutics by 22.2% during the 4th quarter. SG Americas Securities LLC now owns 9,890 shares of the company's stock worth $448,000 after buying an additional 1,796 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Apogee Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company's stock worth $432,000 after acquiring an additional 892 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Apogee Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 52,720 shares of the company's stock worth $2,388,000 after acquiring an additional 1,750 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Apogee Therapeutics by 8.9% in the 4th quarter. New York State Common Retirement Fund now owns 12,187 shares of the company's stock valued at $552,000 after acquiring an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE traded down $0.77 on Friday, reaching $36.92. The company's stock had a trading volume of 534,306 shares, compared to its average volume of 527,849. Apogee Therapeutics, Inc. has a 52-week low of $26.20 and a 52-week high of $63.50. The stock has a market capitalization of $1.70 billion, a P/E ratio of -15.26 and a beta of 1.70. The stock's 50-day moving average is $36.46 and its two-hundred day moving average is $39.83.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. Equities analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Carl Dambkowski sold 3,860 shares of the company's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total value of $139,809.20. Following the completion of the transaction, the insider now directly owns 247,173 shares in the company, valued at approximately $8,952,606.06. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. The trade was a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 18,175 shares of company stock worth $587,191. Company insiders own 42.77% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on APGE shares. Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Wedbush reissued an "outperform" rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Finally, Citigroup initiated coverage on Apogee Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $95.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $94.60.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.